Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSC-sEV for the Treatment of Syringomyelia
NCT07295067Phase 1Active, not recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Dec 2025
- Primary completion
- May 2026
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hucMSC-sEVs in Syringomyelia, sponsored by Xuanwu Hospital. Primary endpoint: Dose-Limiting Toxicities at 12 weeks. Started Dec 2025; status: active, not recruiting.
02
Drugs
hucMSC-sEVs
03
Conditions
Syringomyelia
Beyond the preview
Go deeper on NCT07295067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07295067.